Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data
Aim: There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. Patients & methods: This was a retrospe...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2023-12-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |
| _version_ | 1797323991381180416 |
|---|---|
| author | Julia Pisc Angela Ting Michelle Skornicki Omar Sinno Edward Lee |
| author_facet | Julia Pisc Angela Ting Michelle Skornicki Omar Sinno Edward Lee |
| author_sort | Julia Pisc |
| collection | DOAJ |
| description | Aim: There are limited data on the clinical and economic burden of exacerbations in patients with
myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource
utilization (HCRU) associated with MG exacerbation. Patients & methods: This was a retrospective analysis
of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the
IBM MarketScan database. Eligible patients had two or more MG diagnosis codes, without evidence
of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]).
Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of
exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-
year follow-up period. Results: Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced ≥1
exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6%
(n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and
Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced
by approximately half of commercial and Medicare patients with ≥1 exacerbation. Mean total MG related
healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967
for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple
exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations. Conclusion:
Despite utilization of current treatments for MG,MG exacerbations are associated with a high clinical and
economic burden in both commercial and Medicare patients. Additional treatment options and improved
disease management may help to reduce exacerbations and disease burden. |
| first_indexed | 2024-03-08T05:36:55Z |
| format | Article |
| id | doaj.art-893eec590ce048cabad9b785f6c00274 |
| institution | Directory Open Access Journal |
| issn | 2042-6313 |
| language | English |
| last_indexed | 2024-03-08T05:36:55Z |
| publishDate | 2023-12-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj.art-893eec590ce048cabad9b785f6c002742024-02-05T15:31:01ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132023-12-0113110.57264/cer-2023-0108Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims dataJulia Pisc0Angela Ting1Michelle Skornicki2Omar Sinno3Edward Lee4Aetion Inc., New York, NY 10001, USAUCB Pharma, Atlanta, GA 30080, USAAetion Inc., New York, NY 10001, USAUCB Pharma, Atlanta, GA 30080, USAUCB Pharma, Atlanta, GA 30080, USAAim: There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. Patients & methods: This was a retrospective analysis of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the IBM MarketScan database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2- year follow-up period. Results: Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced ≥1 exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6% (n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with ≥1 exacerbation. Mean total MG related healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations. Conclusion: Despite utilization of current treatments for MG,MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.commercialdatabasediseasemanagementhealthcare costshealthcare resource utilizationibmmarketscanmedicaidmedicarereal-world datatreatmentunited states claims database |
| spellingShingle | Julia Pisc Angela Ting Michelle Skornicki Omar Sinno Edward Lee Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data Journal of Comparative Effectiveness Research commercial database diseasemanagement healthcare costs healthcare resource utilization ibm marketscan medicaid medicare real-world data treatment united states claims database |
| title | Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data |
| title_full | Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data |
| title_fullStr | Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data |
| title_full_unstemmed | Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data |
| title_short | Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data |
| title_sort | healthcare resource utilization costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the usa a retrospective analysis of claims data |
| topic | commercial database diseasemanagement healthcare costs healthcare resource utilization ibm marketscan medicaid medicare real-world data treatment united states claims database |
| work_keys_str_mv | AT juliapisc healthcareresourceutilizationcostsandtreatmentassociatedwithmyastheniagravisexacerbationsamongpatientswithmyastheniagravisintheusaaretrospectiveanalysisofclaimsdata AT angelating healthcareresourceutilizationcostsandtreatmentassociatedwithmyastheniagravisexacerbationsamongpatientswithmyastheniagravisintheusaaretrospectiveanalysisofclaimsdata AT michelleskornicki healthcareresourceutilizationcostsandtreatmentassociatedwithmyastheniagravisexacerbationsamongpatientswithmyastheniagravisintheusaaretrospectiveanalysisofclaimsdata AT omarsinno healthcareresourceutilizationcostsandtreatmentassociatedwithmyastheniagravisexacerbationsamongpatientswithmyastheniagravisintheusaaretrospectiveanalysisofclaimsdata AT edwardlee healthcareresourceutilizationcostsandtreatmentassociatedwithmyastheniagravisexacerbationsamongpatientswithmyastheniagravisintheusaaretrospectiveanalysisofclaimsdata |